Use of sibutramine in obese Hispanic adolescents

Advances in Therapy

Volumn 22, Issue 6, 2005, Pages 642-649

  Violante Ortíz, Rafael ^a   Del Rio Navarro, Blanca Estela ^b   Lara Esqueda, Agustín ^c   Pérez, Pedro ^d   Fanghänel, Guillermo ^e   Madero, Agustín ^f   Berber, Arturo ^b,g  

^a Regional General Hospital   (Mexico)

^b Children's Hospital of Mexico   (Mexico)

^c National Center for Epidemiologic Vigilance   (Mexico)

^d Cemain Hospital   (Mexico)

^e UNIVERSIDAD NACIONAL AUTÓNOMA DE MÉXICO   (Mexico)

^f INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^g Cruz G?lvez 269 CP 02800   (Mexico)

Author keywords

Adolescent; Obesity; Sibutramine; Weight loss

Indexed keywords

PLACEBO; SIBUTRAMINE;

ADOLESCENT; ADULT; ANOREXIA; ARTICLE; BODY MASS; CONSTIPATION; DRUG SAFETY; FEMALE; HEADACHE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PRIVATE PRACTICE; PULSE RATE; RESTLESSNESS; SCHOOL CHILD; TACHYCARDIA; XEROSTOMIA;

EID: 33645024991     PISSN: 0741238X     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF02849958     Document Type: Article

References (19)

1. Centers for Disease Control and Prevention (CDC). Prevalence of overweight among children and adolescents: United States, 1999-2000. Available at: http://www.cdc.gov/nchs/products/ pubs/pubd/hestats/overwghr99.htm. Accessed November 10, 2003.
2. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999-2000. JAMA. 2002;288:1728-1732.
3. Del-Rio-Navarro BE, Velazquez-Monroy O, Sanchez-Castillo CP, et al, and Encuesta Nacional de Salud 2000 Working Group. National Health Survey 2000: the high prevalence of overweight and obesity in Mexican children. Obes Res. 2004;12:215-223.
4. Rodriguez-Moran M, Salazar-Vazquez B, Violante R, Guerrero-Romero F. Metabolic syndrome among children and adolescents aged 10-18 years. Diabetes Care. 2004;27:2516-2517.
5. Williams CL, Hayman LL, Daniels SR, et al. Cardiovascular health in childhood: a statement for health professionals from the Committee on Atherosclerosis, Hypertension, and Obesity in the Young (AHOY) of the Council on Cardiovascular Disease in the Young, American Heart Association. Circulation. 2002;106:143-160.
6. Yanovski JA. Intensive therapies for pediatric obesity. Pediatr Clin North Am. 2001;48:1041-1053.
7. Berkowitz RI, Wadden TA, Tershakovec AM, Cronquist JL. Behavior therapy and sibutramine for the treatment of adolescent obesity: a randomized controlled trial. JAMA. 2003;289:1805-1812.
8. Ogden CL, Kuczmarski RJ, Flegal KM, et al. Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics. 2002;109:45-60.
9. Chen W, Srinivasan SR, Li S, Xu J, Berenson GS. Metabolic syndrome variables at low levels in childhood are beneficially associated with adulthood cardiovascular risk: the Bogalusa Heart Study. Diabetes Care. 2005;28:126-131.
10. McDuffie JR, Calis KA, Uwaifo GI, et al. Efficacy of orlistat as an adjunct to behavioral treatment in overweight African American and Caucasian adolescents with obesity-related co-morbid conditions. J Pediatr Endocrinol Metab. 2004;17:307-319.
11. Bray GA, Blackburn GL, Ferguson JM, et al. Sibutramine produces dose-related weight loss. Obes Res. 1999;7:189-198.
12. James WP, Astrup A, Finer N, et al, STORM Study Group. Effect of sibutramine on weight maintenance after weight loss: a randomised trial. Sibutramine Trial of Obesity Reduction and Maintenance. Lancet. 2000;356:2119-2125.
13. Hansen DL, Toubro S, Stock MJ, MacDonald IA, Astrup A. The effect of sibutramine on energy expenditure and appetite during chronic treatment without dietary restriction. Int J Obes Relat Metab Disord. 1999;23:1016-1024.
14. Cuellar GE, Ruiz AM, Monsalve MC, Berber A. Six-month treatment of obesity with sibutramine 15 mg: a double-blind, placebo-controlled monocenter clinical trial in a Hispanic population. Obes Res. 2000;8:71-82.
15. Fanghanel G, Cortinas L, Sanchez-Reyes L, Berber A. A clinical trial of the use of sibutramine for the treatment of patients suffering essential obesity. Int J Obes Relat Metab Disord. 2000;24:144-150.
16. Benson K, Hartz AJ. A comparison of observational studies and randomized, controlled trials. N Engl J Med. 2000;342:1878-1886.
17. Concato J, Shah N, Horwitz RI. Randomized, controlled trials, observational studies, and the hierarchy of research designs. N Engl J Med. 2000;342:1887-1892.
18. Denzer C, Reithofer E, Wabitsch M, Widhalm K. The outcome of childhood obesity management depends highly upon patient compliance. Eur J Pediatr. 2004;163:99-104.
19. Pinelli L, Elerdini N, Faith MS, et al. Childhood obesity: results of a multicenter study of obesity treatment in Italy. J Pediatr Endocrinol Metab. 1999;12(suppl 3):795-799.